- Home
- IPSC
as 02-21-2025 4:00pm EST
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | 165 | City: | PHILADELPHIA |
| Market Cap: | 62.1M | IPO Year: | 2021 |
| Target Price: | $11.00 | AVG Volume (30 days): | 488.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $5.51 | Next Earning Date: | 03-13-2025 |
| Revenue: | $2,684,000 | Revenue Growth: | 7.88% |
| Revenue Growth (this year): | 230.6% | Revenue Growth (next year): | 31.83% |
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 3 '25 | Sell | $0.78 | 1,054 | $822.12 | 134,076 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Feb 3 '25 | Sell | $0.78 | 351 | $273.78 | 316,796 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
MT Newswires
2 months ago
Piper Sandler Adjusts Price Target on Century Therapeutics to $4 From $12, Keeps Overweight Rating
GlobeNewswire
3 months ago
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Zacks
3 months ago
What Makes Century Therapeutics (IPSC) a New Buy Stock
Simply Wall St.
4 months ago
Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations
MT Newswires
4 months ago
Century Therapeutics Shares Rise After Q3 Beats Estimates
Zacks
4 months ago
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
4 months ago
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Compare IPSC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.